BeOne Medicines Ltd.

BeOne Medicines Ltd. has concluded a statutory tax audit in China, agreeing to a settlement with the local tax authority. This settlement involves an income tax payment of approximately RMB 446 million, which includes surcharges and related interest, for adjustments to previously filed tax returns. The company noted that no administrative penalty was imposed, and the payment is expected to be recognized in its U.S. GAAP financial statements for the second quarter of fiscal 2026.

BeOne Medicines Ltd. shareholders approved significant increases in authorized shares for its equity incentive plans at the Annual General Meeting on June 11, 2026. The 2016 Share Option and Incentive Plan saw an increase of 75,400,000 ordinary shares, and the 2018 Employee Share Purchase Plan increased by 3,250,000 ordinary shares. Additionally, four directors did not stand for re-election, and their terms concluded without any disagreement. Shareholders also approved the 2025 financial statements, appropriation of accumulated loss, and discharged the Board and Executive Management from liability.

BeOne Medicines Ltd. announced that its drug BEQALZI (sonrotoclax) received accelerated approval from the U.S. FDA for treating adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This marks the first and only BCL2 inhibitor approved for MCL in the U.S., aiming to set a new standard of care. The approval is supported by Phase 1/2 study data showing a 52% overall response rate and a 16% complete response rate.

BeOne Medicines Ltd. reported a significant increase in its first quarter 2026 financial results, with total revenues rising to $1.51 billion and net income surging to $227.36 million. The company also saw a substantial improvement in its gross profit and income from operations compared to the same period last year. Cash and cash equivalents also increased, reflecting a strong financial position.

BeOne Medicines Ltd. announced strong first-quarter 2026 financial results, with total global revenues increasing 35% year-over-year to $1.51 billion, driven by a 38% rise in BRUKINSA global sales to $1.1 billion. The company reported diluted GAAP EPS of $1.96 and non-GAAP diluted EPS of $3.24. BeOne also updated its full-year 2026 revenue guidance to a range of $6.3 billion to $6.5 billion and highlighted significant clinical and regulatory advancements, including US FDA Priority Review for TEVIMBRA and the commercial launch of Sonrotoclax in China.

BeOne Medicines Ltd. (ONC) filed its definitive proxy statement for its 2026 Annual General Meeting of Shareholders to be held on June 11, 2026. The company reported a remarkable 2025, achieving GAAP profitability for the first time and generating meaningful cash flow, driven by strong topline revenue growth, including BRUKINSA's $3.9 billion in global revenues. Key proposals for the AGM include the approval of 2025 financial statements, election of directors, and mandates for share issuance and repurchase.

BeOne Medicines Ltd. filed its 2025 Annual Report with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange on April 14, 2026. The report, prepared under PRC GAAP, includes additional financial information for the year ended December 31, 2025, such as gross profit margin, R&D expenses by product, and production, sales, and inventory data. The company also detailed key differences between PRC GAAP and U.S. GAAP, specifically regarding share-based compensation and leasing accounting treatments.

BeOne Medicines Ltd. filed its 2025 Annual Report with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. The report, prepared under PRC GAAP, includes additional financial information such as gross profit margin, R&D expenses by product, and production, sales, and inventory units for the year ended December 31, 2025. The company also detailed key differences between financial information prepared under PRC GAAP and U.S. GAAP, specifically regarding share-based compensation and leasing accounting.